Multiparametric analyses of tumor cell and microenvironmental factors to identify biomarkers of therapy response and disease course in patients with head and neck tumors

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00037656

Enrollment

120

Registered

2026-02-18

Start date

2026-01-01

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C32 C00-C14 C76

Interventions

Group 1: Patients with head and neck tumors who received perioperative and/or neoadjuvant immune checkpoint therapy.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Treatment of a head and neck tumor with neoadjuvant/perioperative immune checkpoint therapy

Exclusion criteria

Exclusion criteria: - Lack of consent - Pregnant and breastfeeding patients - Non-German-speaking individuals if there is no possibility of barrier-free communication in English or if a certified translation is unavailable during the informed consent discussion - Individuals who are chronically incapable of understanding information and providing informed consent

Design outcomes

Primary

Measure	Time frame
Characterization of immune cell infiltrates and identification of biomarkers for therapy response and resistance mechanisms to immune checkpoint therapies.	—

Secondary

Measure	Time frame
Investigation of cellular and soluble factors (tumor-associated exosomes, circulating tumor DNA, immune cell repertoire, tumor-infiltrating lymphocytes) and the impact of human papillomavirus (HPV) infection and genomic integration on clinical outcomes.	—

Countries

Germany

Contacts

Public ContactAdrian Fehn

Universitätklinikum Tübingen - Klinik für Innere Medizin II

adrian.fehn@med.uni-tuebingen.de+4970712987766

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026